Castle Biosciences, Inc. (CSTL)

Market Cap	803.34M +11.4%
Revenue (ttm)	344.23M +3.7%
Net Income	-24.16M
EPS	-0.83
Shares Out	29.73M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	335,627
Open	26.81
Previous Close	27.12
Day's Range	25.76 - 27.03
52-Week Range	14.59 - 44.28
Beta	1.13
Analysts	Strong Buy
Price Target	47.17 (+74.57%)
Earnings Date	Feb 26, 2026

About CSTL

Castle Biosciences, Inc., a molecular diagnostics company, provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett’s esophagus (BE), atopic dermatitis (AD), and uveal melanoma. The company offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test that predicts the likelihood of a positive sentinel lymph node and the risk of metastasis for patients with invasive cutaneous melanoma; TissueCypher, a risk stratification spatialomics test to predict future development of high-grade dysplasi...

• Industry: Diagnostics & Research
• Sector: Healthcare
• IPO Date: Jul 25, 2019
• Employees: 883
• Stock Exchange: NASDAQ
• Ticker Symbol: CSTL
• Website: https://castlebiosciences.com

Analyst Summary

According to 6 analysts, the average rating for CSTL stock is "Strong Buy." The 12-month stock price target is $47.17, which is an increase of 74.57% from the latest price.

Price Target

$47.17

(74.57% upside)

Analyst Consensus: Strong Buy